MedPath

Effect of Iron and Folic Acid tablet and capsule formulation on drug compliance

Phase 4
Completed
Registration Number
CTRI/2018/04/013361
Lead Sponsor
All India Institute of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
208
Inclusion Criteria

•Pregnant women who have not been booked earlier for the current pregnancy and are more than 12 weeks of gestation.

Exclusion Criteria

•Refusal to provide written consent

•Hematological disorder (except Anemia)

•Severe anemia requiring blood transfusion ( <7 gm%)

•Already taking IFA preparations for the current pregnancy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Adherence to tablet and capsule formulation of IFA (pill count and recall method) <br/ ><br>2.Difference between mean hemoglobin level change after 100 days of IFA (Capsule or Tablet) consumption <br/ ><br>Timepoint: At the End of the study (August 2014)
Secondary Outcome Measures
NameTimeMethod
1.Association of IFA adherence with various socio-demographic and other factors <br/ ><br>2.Prevalence of various side effects of IFA preparationTimepoint: At the End of the study (August 2014)
© Copyright 2025. All Rights Reserved by MedPath